Skip to main content

Advertisement

Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Fig. 3

ACR50 response rates through week 52 in the overall population (a) and by anti-TNF status (b, c). *p < 0.0001, p < 0.05 versus placebo. p values adjusted for multiplicity of testing for overall population at week 24. Missing values imputed as nonresponse (nonresponder imputation) through week 52. ACR50 50% improvement in American College of Rheumatology response criteria, IR inadequate response, s.c. subcutaneous, TNF tumor necrosis factor

Back to article page